Literature DB >> 22519592

Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation.

G L V de Oliveira1, K C R Malmegrim, A F Ferreira, R Tognon, S Kashima, C E B Couri, D T Covas, J C Voltarelli, F A de Castro.   

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by T cell-mediated destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycaemia. Recent studies have described that apoptosis impairment during central and peripheral tolerance is involved in T1D pathogenesis. In this study, the apoptosis-related gene expression in T1D patients was evaluated before and after treatment with high-dose immunosuppression followed by autologous haematopoietic stem cell transplantation (HDI-AHSCT). We also correlated gene expression results with clinical response to HDI-AHSCT. We observed a decreased expression of bad, bax and fasL pro-apoptotic genes and an increased expression of a1, bcl-x(L) and cIAP-2 anti-apoptotic genes in patients' peripheral blood mononuclear cells (PBMCs) compared to controls. After HDI-AHSCT, we found an up-regulation of fas and fasL and a down-regulation of anti-apoptotic bcl-x(L) genes expression in post-HDI-AHSCT periods compared to pre-transplantation. Additionally, the levels of bad, bax, bok, fasL, bcl-x(L) and cIAP-1 genes expression were found similar to controls 2 years after HDI-AHSCT. Furthermore, over-expression of pro-apoptotic noxa at 540 days post-HDI-AHSCT correlated positively with insulin-free patients and conversely with glutamic acid decarboxylase autoantibodies (GAD65) autoantibody levels. Taken together, the results suggest that apoptosis-related genes deregulation in patients' PBMCs might be involved in breakdown of immune tolerance and consequently contribute to T1D pathogenesis. Furthermore, HDI-AHSCT modulated the expression of some apoptotic genes towards the levels similar to controls. Possibly, the expression of these apoptotic molecules could be applied as biomarkers of clinical remission of T1D patients treated with HDI-AHSCT therapy.
© 2012 The Authors. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22519592      PMCID: PMC3390481          DOI: 10.1111/j.1365-2249.2012.04583.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  59 in total

Review 1.  beta-Cell death during progression to diabetes.

Authors:  D Mathis; L Vence; C Benoist
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

2.  Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis.

Authors:  M K Sharief; H Matthews; M A Noori
Journal:  J Neuroimmunol       Date:  2003-01       Impact factor: 3.478

Review 3.  Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting beta-cell regeneration.

Authors:  C E B Couri; M C Foss; J C Voltarelli
Journal:  Braz J Med Biol Res       Date:  2006-08-22       Impact factor: 2.590

4.  Separation of blood leucocytes, granulocytes and lymphocytes.

Authors:  A Boyum
Journal:  Tissue Antigens       Date:  1974

Review 5.  Apoptosis in autoimmune diseases.

Authors:  K Eguchi
Journal:  Intern Med       Date:  2001-04       Impact factor: 1.271

6.  Elevated Bcl-X(L) levels correlate with T cell survival in multiple sclerosis.

Authors:  Sonia Waiczies; Alexandra Weber; Jan D Lünemann; Orhan Aktas; Rolf Zschenderlein; Frauke Zipp
Journal:  J Neuroimmunol       Date:  2002-05       Impact factor: 3.478

Review 7.  Apoptosis as a therapeutic tool in rheumatoid arthritis.

Authors:  Richard M Pope
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

Review 8.  Antiviral immune responses: triggers of or triggered by autoimmunity?

Authors:  Christian Münz; Jan D Lünemann; Meghann Teague Getts; Stephen D Miller
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

9.  Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin.

Authors:  D A Schatz; W J Riley; J H Silverstein; D J Barrett
Journal:  Immunopharmacol Immunotoxicol       Date:  1989       Impact factor: 2.730

Review 10.  Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways.

Authors:  F Rieux-Laucat; F Le Deist; A Fischer
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

View more
  13 in total

1.  The non-canonical NF-κB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro.

Authors:  Kira Meyerovich; Makiko Fukaya; Leticia F Terra; Fernanda Ortis; Decio L Eizirik; Alessandra K Cardozo
Journal:  Diabetologia       Date:  2015-12-03       Impact factor: 10.122

Review 2.  Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes.

Authors:  John P Driver; Yi-Guang Chen; Clayton E Mathews
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.

Authors:  G L V de Oliveira; A F Ferreira; E P L Gasparotto; S Kashima; D T Covas; C T Guerreiro; D G Brum; A A Barreira; J C Voltarelli; B P Simões; M C Oliveira; F A de Castro; K C R Malmegrim
Journal:  Clin Exp Immunol       Date:  2016-12-23       Impact factor: 4.330

4.  Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes.

Authors:  V M de Jong; A R van der Slik; S Laban; R van 't Slot; B P C Koeleman; A Zaldumbide; B O Roep
Journal:  Genes Immun       Date:  2016-07-28       Impact factor: 2.676

5.  Bone marrow transplantation reverses new-onset immunoinflammatory diabetes in a mouse model.

Authors:  Cheng-Lan Lv; Jing Wang; Ting Xie; Jian Ouyang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 6.  Progress in immune-based therapies for type 1 diabetes.

Authors:  M von Herrath; M Peakman; B Roep
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

7.  Obesity and endoplasmic reticulum (ER) stresses.

Authors:  Yamini B Tripathi; Vivek Pandey
Journal:  Front Immunol       Date:  2012-08-07       Impact factor: 7.561

8.  Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus.

Authors:  Lei Ye; Li Li; Bing Wan; Minglan Yang; Jie Hong; Weiqiong Gu; Weiqing Wang; Guang Ning
Journal:  Stem Cell Res Ther       Date:  2017-04-18       Impact factor: 6.832

Review 9.  Risks, benefits, and therapeutic potential of hematopoietic stem cell transplantation for autoimmune diabetes.

Authors:  Carlos Eduardo Barra Couri; Maria Carolina de Oliveira; Belinda Pinto Simões
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 5.430

Review 10.  Challenges and Opportunities for Biomarkers of Clinical Response to AHSCT in Autoimmunity.

Authors:  Kristina M Harris; Tingting Lu; Noha Lim; Laurence A Turka
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.